ABOUT THIS EPISODE
In this episode of The Connect Current, host James Zanewicz sits down with Gian Luca Araldi, PhD, PharmD, MBA, PMP and Founder/CEO of Avanti Biosciences, to explore the challenge of developing new therapies for fibrotic diseases and what it takes to advance promising science toward the clinic.
Gian Luca shares how Avanti Biosciences is developing novel small-molecule therapies for conditions like idiopathic pulmonary fibrosis, an area of significant unmet medical need. The conversation explores the long path from discovery to clinical development, the role of regulatory milestones and non-dilutive funding, and why translating scientific insight into patient impact requires both innovation and disciplined execution.
As one of Connect's 2026 Cool Companies, Avanti represents the next generation of San Diego life sciences companies working to turn breakthrough research into meaningful therapeutic opportunities. This episode offers a look at the intersection of biotech innovation, drug development, and the future of precision medicine.
Gian Luca shares how Avanti Biosciences is developing novel small-molecule therapies for conditions like idiopathic pulmonary fibrosis, an area of significant unmet medical need. The conversation explores the long path from discovery to clinical development, the role of regulatory milestones and non-dilutive funding, and why translating scientific insight into patient impact requires both innovation and disciplined execution.
As one of Connect's 2026 Cool Companies, Avanti represents the next generation of San Diego life sciences companies working to turn breakthrough research into meaningful therapeutic opportunities. This episode offers a look at the intersection of biotech innovation, drug development, and the future of precision medicine.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of The Connect Current.
OTHER EPISODES IN THIS PODCAST
In this episode of The Connect Current, we sit down with James Mackay, Ph.D., President and CEO of Crystalys Therapeutics, to explore how the company is advancing a new treatment path for people living with gout. James shares how Crystalys is developing dotinurad, a next-generation, once-daily oral…
In this episode of The Connect Current, we sit down with Scott Tait to explore how San Diego can better connect national security needs, university research, dual-use startups, capital, and policy into a stronger innovation system. Drawing on his 27-year Navy career and his work across Lumetec, Sta…
In this episode of The Connect Current, we sit down with Niren Shah, PharmD, MBA, Co-founder and CEO of Cove Therapeutics, to explore one of the biggest challenges in genetic medicine: delivery. Niren shares how Cove is developing non-lipid, non-viral biodegradable polymeric nanoparticles designed …
In this episode of The Connect Current, we sit down with Stanley Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to explore how targeted cancer therapies can create better options for patients facing difficult diseases. Stanley shares the story behind A28’s targeted oncolytic peptide platform,…
In this episode of The Connect Current, we sit down with Ramesh Ramji, Founder and CEO of SpectralTx, to explore how spectral hyperplexing technology could help reshape molecular screening and the future of connected data. Ramesh shares how SpectralTx is developing tools like Spectra-Gel and SpELs …
Disclaimer: The podcast and artwork embedded on this page are from Connect, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
